WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Testclear
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
CELL AND GENE THERAPY
PerkinElmer | September 18, 2021
PerkinElmer, Inc.a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion. The acquisition, the largest in PerkinElmer’s history, further expands the Company’s life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant protei...
MEDTECH
Roche | January 25, 2021
Roche declares that, on 14 December, 2020, it marked a Global Business Partnership Agreement* (GBP) with Sysmex. Under this new system, the gatherings restored their obligation to the long standing Distribution, Sales and Service (DSS) arrangement, permitting Roche to keep on disseminating Sysmex hematology items, including instruments and reagents. This GBP sees the presentation of an IT Solutions Collaboration Agreement. In the recently characterized joint effort, the two organizations have co...
Phylagen | July 31, 2020
Phylagen, an award-winning biotech company specializing in decoding the environmental microbiome for indoor safety, today announced the national availability of its Phylagen Surface™ SARS-CoV-2 (COVID-19) test kit. Designed to be used by anyone on any surface, Phylagen Surface™ provides an early indication of outbreaks in shared spaces including nursing homes, schools, hospitals, restaurants, offices and retail shops."Surface testing can help curb the spread of COVID-19 bu...
INDUSTRIAL IMPACT
LinKinVax technology | February 04, 2022
LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action. LinKinVax is developing a vaccine platform that directly targets dendritic cells.These cells play a crucial role in the immune system, stimulating and regulating immune responses. The agreement with Inserm Transfert covers industrial and commercial use, and the...
Article
MEDICAL
Video
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE